Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
JNJ-303 is an inhibitor of voltage-gated potassium channel Kv7.1 (IC50 = 0.064 µM).1 It is selective for inhibiting Kv7.1 currents (IKs) over INa, IKr, Ito, IK1, and ICaL (IC50s =3.3, 12.6, 11.1, >100, and >10 µM, respectively). It selectively inhibits the heteromeric Kv7.1-KCNE1 complex (IC50 = 0.0784 µM) with no effect on homomeric Kv7.1, Kv7.2, or Kv1.5 in Xenopus oocytes at 1 µM.2 JNJ-303 prolongs the QT interval and also induces pause-dependent torsade de pointes (TdP) in anesthetized dogs when used at doses of 0.63 and 1.25 mg/kg, respectively.1
WARNING This product is not for human or veterinary use.
1. Blockade of the IKS potassium channel: An overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60(1), 1-10 (2009).
2. KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting. Nat. Commun. 7, 12795 (2016).